| Code | CSB-RA004888MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to FMC63, targeting CD19, a critical B-cell surface glycoprotein that plays an essential role in B-cell development, activation, and antibody production. CD19 functions as a co-receptor that modulates B-cell receptor signaling by lowering the threshold for antigen-mediated activation. This protein is expressed throughout B-cell development from pre-B cells to mature B cells, making it an important marker for B-cell lineage identification. CD19 is particularly relevant in hematological malignancies, including B-cell acute lymphoblastic leukemia, chronic lymphocytic leukemia, and various B-cell lymphomas, where it remains consistently expressed on malignant cells.
FMC63 is a well-established mouse monoclonal antibody that has gained prominence as the foundation for CAR-T cell therapies targeting CD19-positive malignancies. This biosimilar provides researchers with a valuable tool for investigating B-cell biology, studying CD19-mediated signaling pathways, and developing novel immunotherapeutic approaches. The antibody supports diverse research applications in oncology, immunology, and cell therapy development.
There are currently no reviews for this product.